Home Newsletters Dermal Cell News Verrica Pharmaceuticals Announces FDA Acceptance of its IND Application for LTX-315, a...

Verrica Pharmaceuticals Announces FDA Acceptance of its IND Application for LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma

By
Justin.choi
-
0
Verrica Pharmaceuticals, Inc. announced that the US FDA has accepted the company’s Investigational New Drug Application (IND) for LTX-315 for the treatment of basal cell carcinoma.
[Verrica Pharmaceuticals, Inc.]

Sorry, but the selected Zotpress account can't be found.

Press Release

RELATED ARTICLES

Exit mobile version